Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/77989
Title: Tpmt*3c as a predictor of 6-mercaptopurine-induced myelotoxicity in thai children with acute lymphoblastic leukemia
Authors: Thawinee Jantararoungtong
Supaporn Wiwattanakul
Rawiporn Tiyasirichokchai
Santirhat Prommas
Rattanaporn Sukprasong
Napatrupron Koomdee
Pimonpan Jinda
Jiratha Rachanakul
Nutthan Nuntharadthanaphong
Samart Pakakasama
Usanarat Anurathapan
Suradej Hongeng
Chonlaphat Sukasem
Ramathibodi Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Srinakharinwirot University
Keywords: Medicine
Issue Date: 1-Aug-2021
Citation: Journal of Personalized Medicine. Vol.11, No.8 (2021)
Abstract: The response to 6-mercaptopurine (6-MP) can be altered by genetic polymorphisms in genes encoding drug-metabolizing enzymes and drug transporters. The purpose of this study was to investigate the association between genetic polymorphisms of drug-metabolizing enzymes (TPMT 719A > G (*3C), ITPA 94C > A and ITPA 123G > A) and drug transporters (MRP4 912C > A and MRP4 2269G > A) with 6-MP-related myelotoxicity and hepatotoxicity in Thai children with acute lymphoblastic leukemia (ALL). The prescribed dosage of 6-MP and its adverse effects were assessed from medical records during the first 8 weeks and 9–24 weeks of maintenance therapy. Children with the TPMT*1/*3C genotype had a higher risk of leukopenia with an odds ratio (OR) of 4.10 (95% confidence interval (CI) of 1.06–15.94; p = 0.033) compared to wild type (TPMT*1/*1) patients. Heterozygous TPMT*3C was significantly associated with severe neutropenia with an increased risk (OR, 4.17; 95% CI, 1.25–13.90); p = 0.014) during the first 8 weeks. No association was found among ITPA 94C > A, ITPA 123G > A, MRP4 912C > A, and MRP4 2269G > A with myelotoxicity and hepatotoxicity. The evidence that TPMT heterozygotes confer risks of 6-MP-induced myelotoxicity also supports the convincing need to genotype this pharmacogenetic marker before the initiation of 6-MP therapy.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/77989
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85113156828&origin=inward
ISSN: 20754426
Appears in Collections:Scopus 2021

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.